Evidence map›Paper›PMID 36240541›Full record

ArticleBioorganic chemistry2022

Acriflavine and proflavine hemisulfate as potential antivirals by targeting M

Jing Liang, Mengzhu Zheng, Wei Xu, Yongkang Chen, Piyu Tang, Guoyi Wu, Peng Zou, Hua Li, Lixia Chen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Jing LiangWuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
Mengzhu ZhengSchool of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Wei XuKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai 200032, China.
Yongkang ChenKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai 200032, China.
Piyu TangWuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
Guoyi WuShanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China. Electronic address: wuguoyi@163.com.
Peng ZouShanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China. Electronic address: zoupeng@shphc.org.cn.
Hua LiWuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China; Institute of Structural Pharmacology & TCM Chemical Biology, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China; School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: li_hua@hust.edu.cn.
Lixia ChenWuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: syzyclx@163.com.
Shenyang Pharmaceutical University · CNFudan University · CNShanghai Public Health Clinical Center · CNHuazhong University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The evolving SARS-CoV-2 epidemic buffets the world, and the concerted efforts are needed to explore effective drugs. M

Indexed as

AcriflavineCoronavirus 3C ProteasesCOVID-19 Drug TreatmentCysteine Proteinase InhibitorsProflavineSARS-CoV-2Viral Protease InhibitorsAnimalsCell LineCricetinaeMesocricetusVirus Replication3C-like proteinase, SARS-CoV-2AcriflavineCoronavirus 3C ProteasesCysteine Proteinase InhibitorsProflavineViral Protease InhibitorsAcriflavineM(pro) inhibitorProflavine hemisulfateSARS-CoV-2

Identifiers

PMID36240541
PMCPMC9540699
OpenAlexW4303438642

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.